

Aerial View

Morning Briefing

Nov 11, 2020

Euro Carry Hope on Vaccine

- **Europe's reflation hopes recover on vaccine optimism**
- **Likely early deployment of fiscal will contain economic scarring**
- **Despite spot moves, EUR carry interest not uniform**



Geoff Yu
Senior EMEA Market Strategist

[Email >](#)

This week's momentous news of a potentially successful vaccine for COVID-19 has triggered one of the biggest rotations in asset markets in recent memory.


Unsurprisingly, the eurozone equities market has been a major beneficiary as its value heavy components finally found favor.

In hindsight, the moves have also revealed the extent of underweight positioning in eurozone assets. So far, the move has not extended materially into FX, but we do see prospects for this to change as Europe's fiscal follow-through remains underappreciated by markets.

Since the vaccine news broke, eurozone inflation expectations have actually moved more than in the US. As the chart below shows, US 5y5y forward breakevens are actually still below levels seen just after the election.

It is true that eurozone inflation expectations are coming off a much lower base (exacerbated by lockdowns in Germany and France), giving them greater scope to move higher, but it is still the fiscal response that sets the eurozone apart from G5 counterparts.

Change in Inflation Expectations, Past Week



Source: BNY Mellon Markets, Bloomberg L.P.

Political responses on fiscal policy could not be more different on each side of the Atlantic.

While Senate Majority Leader Mitch McConnell saw the vaccine news as an opening to reduce the amount of stimulus which could be deployed, the eurozone has just overcome certain political hurdles to agree the Next Generation EU rescue fund and a multi-year budget to start deployment as soon as mid-next year.

The stated aim of spending 70% of the NGEU funding over the next two years remain in place and will go far in boosting the eurozone's inflation and growth outlook, or at least ensuring that the 2021-2022 macroeconomic projections to be announced in December will not face serious downward revision.

The projections also have a very specific baseline assumption on a vaccine, whereas the ECB expects "a satisfactory medical solution (such as a vaccine) is assumed to be found by mid-2021, with a gradual widespread deployment by the end of 2021".

Suffice to say the medical community is probably on track to meet, or even outperform, the baseline.

The ECB expects "a satisfactory medical solution (such as a vaccine) to be found by mid-2021, with a gradual widespread deployment by the end of 2021"

On the other hand, we do not see the vaccine news as changing the short-term path for

the ECB.

The Governing Council was quite clear about the need for additional easing in response to the new lockdowns in Germany, France and elsewhere in Europe, which were also not part of its baseline assumption, which suggested that the spring lockdowns would not be repeated this winter.

Leading indicators, especially in the services sector, were already deteriorating heading into November, increasing the scope for economic scarring which needed to be offset through monetary and fiscal stimulus.

So far, the eurozone is the only major pandemic-affected economy where such stimulus has been sustained throughout lockdowns and in a consistent manner.


The US is no closer to a new dose of fiscal support, while the UK's initial piecemeal and latterly comprehensive extension to the furlough scheme has likely generated too much uncertainty for employers' liking.

Returning to asset markets, the euro is also starting to claw back attractiveness, especially in equity markets. The chart below shows European dividend yields hedged backed into local G5 currencies, measured against the dividend yield of local benchmarks. At 2.80% hedged, levels are already attractive on an outright basis.

For USD, GBP and JPY investors, hedging back into local currency will generate additional yield pickup due to favorable rate differentials. Dollar and yen investors can pick-up an additional 150-200bps through these strategies, and even GBP-based investors who traditionally enjoy high dividend yields via the FTSE100 can afford to give eurozone equities an additional glance.

The Swiss market remains the outlier, where both absolute dividend yields and rate differentials both work against such a strategy.

Eurozone Stoxx 600 Dividend Yield (Hedged) vs. Local Market Dividend Yield




Source: BNY Mellon, Bloomberg LP

In euro currency pairs, the reaction has not been uniform either. We set aside initial spot movements and look at the options curve to see if there has been any fundamental shift in the euro's expectations.

As the chart below shows, in a manner consistent with the improvement in equity performance, risk reversals in EURUSD and EURJPY have moved materially across the term structure in favor of euro calls. However, EURCHF is unimpressed by recent developments and sterling seems to have achieved an even bigger bounce from vaccine news.

Change in EUR- Risk Reversals, Oct 30 - Nov 6



Source: BNY Mellon, Bloomberg LP

EURCHF is unimpressed by recent developments and sterling seems to have achieved an even bigger bounce from vaccine news

Much of the improvement in sterling demand also stems from a low growth/inflation base, while there may be some additional tailwinds from Brexit developments.

On the other hand, we believe the fiscal divergence between the UK and eurozone is continuing to widen and this will have a material impact on growth differentials in upcoming quarters.

In our [previous notes](#) we have highlighted how the eurozone continues to struggle with achieving credibility on reflation as the market always imposes a higher bar compared to economies with higher potential growth.

These are structural aspects which will take time to resolve, but we should not conflate

these issues with the medium-term outlook, where the eurozone is far better positioned compared to its peers.

Please direct questions or comments to:

AerialView@BNYMellon.com

Disclaimer

bnymellon.com

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may be used as a generic term to reference the corporation as a whole and/or its various subsidiaries generally. This material and any products and services may be issued or provided under various brand names in various countries by duly authorized and regulated subsidiaries, affiliates, and joint ventures of BNY Mellon, which may include any of the following. The Bank of New York Mellon, at 225 Liberty St, NY, NY USA, 10286, a banking corporation organized pursuant to the laws of the State of New York, and operating in England through its branch at One Canada Square, London E14 5AL, UK, registered in England and Wales with numbers FC005522 and BR000818. The Bank of New York Mellon is supervised and regulated by the New York State Department of Financial Services and the US Federal Reserve and authorized by the Prudential Regulation Authority. The Bank of New York Mellon, London Branch is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. The Bank of New York Mellon SA/NV, a Belgian public limited liability company, with company number 0806.743.159, whose registered office is at 46 Rue Montoyerstraat, B-1000 Brussels, Belgium, authorized and regulated as a significant credit institution by the European Central Bank (ECB), under the prudential supervision of the National Bank of Belgium (NBB) and under the supervision of the Belgian Financial Services and Markets Authority (FSMA) for conduct of business rules, and a subsidiary of The Bank of New York Mellon. The Bank of New York Mellon SA/NV operates in England through its branch at 160 Queen Victoria Street, London EC4V 4LA, UK, registered in England and Wales with numbers FC029379 and BR014361. The Bank of New York Mellon SA/NV (London Branch) is authorized by the ECB and subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request. The Bank of New York Mellon SA/NV operating in Ireland through its branch at 4th Floor Hanover Building, Windmill Lane, Dublin 2, Ireland trading as The Bank of New York Mellon SA/NV, Dublin Branch, is authorised by the ECB and is registered with the Companies Registration Office in Ireland No. 907126 & with VAT No. IE 9578054E. The Bank of New York Mellon, Singapore Branch, subject to regulation by the Monetary Authority of Singapore. The Bank of New York Mellon, Hong Kong Branch, subject to regulation by the Hong Kong Monetary Authority and the Securities & Futures Commission of Hong Kong. If this material is distributed in Japan, it is distributed by The Bank of New York Mellon Securities Company Japan Ltd, as intermediary for The Bank of New York Mellon. If this material is distributed in, or from, the Dubai International Financial Centre ("DIFC"), it is communicated by The Bank of New York Mellon, DIFC Branch, regulated by the DFSA and located at DIFC, The Exchange Building 5 North, Level 6, Room 601, P.O. Box 506723, Dubai, UAE, on behalf of The Bank of New York Mellon, which is a wholly-owned subsidiary of The Bank of New York Mellon Corporation. This material is intended for Professional Clients only and no other person should act upon it. Not all products and services are offered in all countries.

The information contained in this material is intended for use by wholesale/professional clients or the equivalent only and is not intended for use by retail clients. If distributed in the UK, this material is a financial promotion.

This material, which may be considered advertising, is for general information purposes only and is not intended to provide legal, tax, accounting, investment, financial or other professional advice on any matter. This material does not constitute a recommendation by BNY Mellon of any kind. Use of our products and services is subject to various regulations and regulatory oversight. You should discuss this material with appropriate advisors in the context of your circumstances before acting in any manner on this material or agreeing to use any of the referenced products or services and make your own independent assessment (based on such advice) as to whether the referenced products or services are appropriate or suitable for you. This material may not be comprehensive or up to date and there is no undertaking as to the accuracy, timeliness, completeness or fitness for a particular purpose of information given. BNY Mellon will not be responsible for updating any information contained within this material and opinions and information contained herein are subject to change without notice. BNY Mellon assumes no direct or consequential liability for any errors in or reliance upon this material.

This material may not be distributed or used for the purpose of providing any referenced products or services or making any offers or solicitations in any jurisdiction or in any circumstances in which such products, services, offers or solicitations are unlawful or not authorized, or where there would be, by virtue of such distribution, new or additional registration requirements.

The terms of any products or services provided by BNY Mellon to a client, including without limitation any administrative, valuation, trade execution or other services shall be solely determined by the definitive agreement relating to such products or services. Any products or services provided by BNY Mellon shall not be deemed to have been provided as fiduciary or adviser except as expressly provided in such definitive agreement. BNY Mellon may enter into a foreign exchange transaction, derivative transaction or collateral arrangement as a counterparty to a client, and its rights as counterparty or secured party under the applicable transactional agreement or collateral arrangement shall take precedence over any obligation it may have as fiduciary or adviser or as service provider under any other agreement.

Pursuant to Title VII of The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the applicable rules thereunder, The Bank of New York Mellon is provisionally registered as a swap dealer with the Commodity Futures Trading Commission ("CFTC") and is a swap dealer member of the National Futures Association (NFA ID 0420990).

BNY Mellon (including its broker-dealer affiliates) may have long or short positions in any currency, derivative or instrument discussed herein. BNY Mellon has included data in this material from information generally available to the public from sources believed to be reliable. Any price or other data used for illustrative purposes may not reflect actual current conditions. No representations or warranties are made, and BNY Mellon assumes no liability, as to the suitability of any products and services described herein for any particular purpose or the accuracy or completeness of any information or data contained in this material. Price and other data are subject to change at any time without notice.

Rates: neither BNY Mellon nor any other third party provider shall be liable for any errors in or delays in providing or making available the data (including rates, WM/Reuters Intra-Day Spot Rates and WM/Reuters Intra-Day Forward Rates) contained within this service or for any actions taken in reliance on the same, except to the extent that the same is directly caused by its or its employees' negligence. The WM/Reuters Intra-Day Spot Rates and WM/Reuters Intra-Day Forward Rates are provided by The World Markets Company plc ("WM") in conjunction with Reuters. WM shall not be liable for any errors in or delays in providing or making available the data contained within this service or for any actions taken in reliance on the same, except to the extent that the same is directly caused by its or its employees' negligence.

The products and services described herein may contain or include certain "forecast" statements that may reflect possible future events based on current expectations. Forecast statements are neither historical facts nor assurances of future performance. Forecast statements typically include, and are not limited to, words such as "anticipate", "believe", "estimate", "expect", "future", "intend", "likely", "may", "plan", "project", "should", "will", or other similar terminology and should NOT be relied upon as accurate indications of future performance or events. Because forecast statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. iFlow® is a registered trademark of The Bank of New York Mellon Corporation under the laws of the United States of America and other countries.

This document is intended for private circulation. Persons accessing, or reading, this material are required to inform themselves about and to observe any restrictions that apply to the distribution of this information in their jurisdiction.

Currency Administration is provided under and subject to the terms of a definitive agreement between BNY Mellon and the client. BNY Mellon exercises no investment discretion thereunder, but acts solely pursuant to the instructions in such agreement or otherwise provided by the client. Unless provided by definitive agreement, BNY Mellon is not an agent or fiduciary thereunder, and acts solely as principal in connection with related foreign exchange transactions.

All references to dollars are in US dollars unless specified otherwise.

This material may not be reproduced or disseminated in any form without the prior written permission of BNY Mellon. Trademarks, logos and other intellectual property marks belong to their respective owners.

The Bank of New York Mellon, member FDIC.

© 2020 The Bank of New York Mellon Corporation. All rights reserved.